For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three to six times each week. "It's been a ...

AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad hypophosphatasia (HPP) patient population. HPP is a rare, inherited metabolic disorder ...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week. It's been a ...

AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic bone disorder. The global programme included two ...

Hypophosphatasia (HPP) is a rare genetic disorder that affects bone and teeth development. Doctors tailor treatment for HPP to the individual. Sometimes no treatment is necessary, but various ...

A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the company’s ability to expand beyond the children served by its existing drug.

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week. “It's been a ...